GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ember Therapeutics Inc (OTCPK:EMBT) » Definitions » Notes Receivable

Ember Therapeutics (Ember Therapeutics) Notes Receivable : $0.00 Mil (As of Sep. 2015)


View and export this data going back to 2015. Start your Free Trial

What is Ember Therapeutics Notes Receivable?

Ember Therapeutics's Notes Receivable for the quarter that ended in Sep. 2015 was $0.00 Mil.


Ember Therapeutics Notes Receivable Historical Data

The historical data trend for Ember Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ember Therapeutics Notes Receivable Chart

Ember Therapeutics Annual Data
Trend Dec12 Dec13 Dec14
Notes Receivable
- - -

Ember Therapeutics Quarterly Data
Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ember Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Ember Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of Ember Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Ember Therapeutics (Ember Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
135 East 57th Street, 24th Floor, New York, NY, USA, 10022
Ember Therapeutics Inc is engaged in the healthcare sector. It is a biopharmaceutical company whose primary focus is on utilizing Bone Morphogenetic Protein-7 (BMP-7) and related family of BMPs, mutants, variants, novel formulations, and delivery technologies. It looks to develop regenerative medicines for disease modification of osteoarthritis, reversal of insulin resistance, and the inhibition and reversal of organ fibrosis in diseases such as chronic kidney disease and Alport Syndrome.

Ember Therapeutics (Ember Therapeutics) Headlines

From GuruFocus